Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates (ADCs) for cancer treatment, will host its Q2 2025 earnings conference call on August 13, 2025, at 8:00 a.m. ET. The company will provide business updates and financial results for the quarter ended June 30, 2025.
Investors can access the call via phone at 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast will be available on Mersana's website, with a replay accessible for approximately 90 days after the call.
Mersana Therapeutics (NASDAQ: MRSN), un'azienda biofarmaceutica in fase clinica specializzata in coniugati anticorpo-farmaco (ADC) per il trattamento del cancro, terr脿 la sua conference call sui risultati del secondo trimestre 2025 il 13 agosto 2025 alle 8:00 ET. La societ脿 fornir脿 aggiornamenti aziendali e i risultati finanziari per il trimestre terminato il 30 giugno 2025.
Gli investitori potranno partecipare alla chiamata telefonando al 833-255-2826 (nazionale) oppure al 412-317-0689 (internazionale). Una diretta web sar脿 disponibile sul sito di Mersana, con la possibilit脿 di riascoltare la registrazione per circa 90 giorni dopo la chiamata.
Mersana Therapeutics (NASDAQ: MRSN), una compa帽铆a biofarmac茅utica en etapa cl铆nica especializada en conjugados anticuerpo-f谩rmaco (ADC) para el tratamiento del c谩ncer, realizar谩 su conferencia telef贸nica de resultados del segundo trimestre de 2025 el 13 de agosto de 2025 a las 8:00 a.m. ET. La empresa proporcionar谩 actualizaciones comerciales y resultados financieros correspondientes al trimestre finalizado el 30 de junio de 2025.
Los inversionistas pueden acceder a la llamada por tel茅fono al 833-255-2826 (nacional) o al 412-317-0689 (internacional). Habr谩 una transmisi贸n en vivo disponible en el sitio web de Mersana, con una repetici贸n accesible durante aproximadamente 90 d铆as despu茅s de la llamada.
Mersana Therapeutics (NASDAQ: MRSN)電� 頃泊-鞎诫 鞝戫暕觳�(ADC)毳� 鞚挫毄頃� 鞎� 旃橂鞐� 韸鬼檾霅� 鞛勳儊 雼硠 氚旍澊鞓れ牅鞎� 須岇偓搿滌劀, 2025雲� 8鞗� 13鞚� 鞓れ爠 8鞁�(霃欕秬 鞁滉皠)鞐� 2025雲� 2攵勱赴 鞁れ爜 旎嵓霟办姢 旖�鞚� 臧滌禍頃╇媹雼�. 須岇偓電� 2025雲� 6鞗� 30鞚� 膦呺霅� 攵勱赴鞚� 靷梾 順勴櫓 氚� 鞛 瓴瓣臣毳� 氚滍憸頃� 鞓堨爼鞛呺媹雼�.
韴瀽鞛愲摛鞚赌 甑偞 鞝勴檾 833-255-2826 霕愲姅 甑牅 鞝勴檾 412-317-0689毳� 韱淀暣 旖滌棎 彀胳棳頃� 靾� 鞛堨姷雼堧嫟. Mersana 鞗轨偓鞚错姼鞐愳劀 鞁れ嫓臧� 鞗轨簮鞀ろ姼臧� 鞝滉车霅橂┌, 旖� 膦呺 頉� 鞎� 90鞚缄皠 鞛箔旆皜 臧�電ロ暕雼堧嫟.
Mersana Therapeutics (NASDAQ : MRSN), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans les conjugu茅s anticorps-m茅dicaments (ADC) pour le traitement du cancer, tiendra sa conf茅rence t茅l茅phonique sur les r茅sultats du deuxi猫me trimestre 2025 le 13 ao没t 2025 脿 8h00 ET. La soci茅t茅 fournira des mises 脿 jour commerciales et les r茅sultats financiers pour le trimestre clos le 30 juin 2025.
Les investisseurs pourront acc茅der 脿 l鈥檃ppel par t茅l茅phone au 833-255-2826 (national) ou au 412-317-0689 (international). Une diffusion en direct sera disponible sur le site web de Mersana, avec un replay accessible pendant environ 90 jours apr猫s l鈥檃ppel.
Mersana Therapeutics (NASDAQ: MRSN), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Antik枚rper-Wirkstoff-Konjugate (ADCs) zur Krebsbehandlung spezialisiert hat, wird seine Telefonkonferenz zu den Ergebnissen des zweiten Quartals 2025 am 13. August 2025 um 8:00 Uhr ET abhalten. Das Unternehmen wird Gesch盲ftsaktualisierungen und Finanzberichte f眉r das am 30. Juni 2025 endende Quartal pr盲sentieren.
Investoren k枚nnen 眉ber die Telefonnummer 833-255-2826 (national) oder 412-317-0689 (international) an der Telefonkonferenz teilnehmen. Ein Live-Webcast wird auf der Website von Mersana verf眉gbar sein, mit einer Wiedergabeoption f眉r etwa 90 Tage nach der Konferenz.
- None.
- None.
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2025 on Wednesday, August 13, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at聽, and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that have generated a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the 鈥淚nvestors & Media鈥� section of its website at聽.
Contact:
FAQ
When is Mersana Therapeutics (MRSN) Q2 2025 earnings call?
How can investors access Mersana Therapeutics Q2 2025 earnings call?
How long will the MRSN Q2 2025 earnings call replay be available?
What does Mersana Therapeutics (MRSN) specialize in?
